Ibrutinib-induced severe liver injury.
Clin Case Rep
; 5(6): 735-738, 2017 06.
Article
em En
| MEDLINE
| ID: mdl-28588800
ABSTRACT
Ibrutinib, an inhibitor of the Bruton's tyrosine kinase of the B-cell receptor pathway, is an effective therapeutic agent for B-cell lymphomas. As these drugs are novel, long-term or rare adverse events are not yet known. We report the first case of ibrutinib-induced severe liver injury in a patient with relapsed/refractory CLL.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article